Careers  |  Sign In  |  Register  |   Twitter

Pharma Companies Vying To Develop C. Diff Treatment

When in the hospital, many patients contract a secondary infection known as C. difficile, an infection that disrupts the healthy bacteria in the intestine and causes diarrhea and intestinal bleeding. Bloomberg News reports that until now companies have focused on more profitable anti-infection drugs, such as diabetes drugs but now companies such as Merck, Sanofi, Actelion Ltd. and Shire Plc are vying to develop products to control or prevent C. diff. Experts say that we will see a resurgence in the development of drugs for hospital-based infections because “the incidence of U.S. cases almost doubled in the first decade of this century, according to the Atlanta-based Centers for Disease Control and Prevention.”

Read the article published by Bloomberg News.